In November 2020, Revance announced results from a Phase 2 clinical trial evaluating DaxibotulinumtoxinA for Injection for the management of plantar fasciitis. Revance plans to analyze the data further for additional insights, however our primary focus will be on neurological indications, where the market and path to approval are well established.
Plantar Fasciitis in Numbers
Will suffer in U.S.
What is Plantar Fasciitis? With Dr. Walter Strash
Beyond plantar fasciitis, Revance is continuing to study DaxibotulinumtoxinA for Injection in other important therapeutic indications with a current focus in muscle movement disorders.
DaxibotulinumtoxinA for Injection has delivered highly positive Phase 3 results, including strong duration of effect, demonstrating a median duration of 24 weeks in the treatment of glabellar lines and cervical dystonia.
1. Mayo Clinic Web Site. https://www.mayoclinic.org/diseases-conditions/plantar-fasciitis/symptoms-causes/syc-20354846. Accessed 8/11/20
2. Schneider H. et al. ACFS Clinical Consenus Statement. Journal of Foot and Ankle Surgery 2017
3. Tehririan MA et al. Plantar Fasciitis. J Res Med Sci. 2012 Aug; 17(8): 799–804